<DOC>
	<DOCNO>NCT01975818</DOCNO>
	<brief_summary>Evaluate efficacy safety 16 week titrate dose treatment BAY85-3934 versus epoetin alfa/beta measure hemoglobin ( Hb ) level . Fixed start dos 25 , 50,75 150 mg BAY85-3934 titrate schedule dose control visit . Titration base subject 's Hb response tolerability prior dose . Planned dos include 15 , 25 , 50 , 75 , 100,150 200 mg/day</brief_summary>
	<brief_title>Maintenance Treatment Anemia Associated With Chronic Kidney Disease ( CKD ) Hemodialysis Subjects Epoetin Alfa / Beta Treatment Versus BAY85-3934</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<mesh_term>Hematinics</mesh_term>
	<criteria>Eligible subject diagnosis anemia associate CKD ( chronic kidney disease ) . Women without childbearing potential Male female subject ≥ 18 year age anemia CKD screen On dialysis , define regular longterm hemodialysis , modality dialysis ≥ 3 month randomization Dialysis vascular access via native arteriovenous fistula , synthetic graft , longterm catheter , longterm tunnel catheter Treated epoetin alfa ( US Japan ) epoetin beta ( Japan ) via intravenous ( IV ) subcutaneous ( SC ) route , stable dosing define &lt; 50 % change maximum prescribed weekly dose change prescribe frequency last 8 week prior randomization At least one kidney Mean screening Hb concentration 9.0 11.5 g/dL inclusive ( mean local laboratory Hb measurement [ least 2 measurement must take ≥ 2 day apart ] 4 week screening period , AND none measurement &lt; 9.0 g/dL &gt; 12.0 g /dL Serum ferritin level ≥ 100 μg/L OR transferrin saturation ≥ 20 % screening . Iron substitution allow Folate vitamin B12 level low limit normal . Supplementation allow Subjects significant acute chronic bleeding , overt gastrointestinal bleeding Hereditary hemoglobinopathy ( include , limited , sickle cell disease , beta thalassemia , thalassemia major ) may primary cause anemia Chronic lymphoproliferative disease Any allograft ( include renal allograft ) place immunosuppressive therapy , schedule kidney transplant within next 16 week ( wait list exclude subject ) Chronic inflammatory disease could impact erythropoiesis ( e.g. , systemic lupus erythematosis , rheumatoid arthritis , celiac disease ) Subjects treated immuno myelosuppressive therapy within 8 week prior randomization : e.g. , everolimus , sirolimus , rituximab , azathioprine , mycophenolate mofetil , mycophenolic acid , cyclosporine , methotrexate , tacrolimus , chemotherapeutic agent anticancer agent , systemic steroid ( except inhale steroid ) 7 day RBCcontaining transfusion within 8 week randomization History cardio ( cerebro ) vascular event ( e.g. , unstable angina , myocardial infarction , stroke , transient ischemic attack , deep vein thrombosis , pulmonary embolism ) within last 6 month initial screen visit Sustained , poorly control arterial hypertension hypotension screening , define mean BP ≥ 180/110 mmHg systolic BP &lt; 95 mmHg , respectively Severe rhythm conduction disorder ( e.g. , HR &lt; 50 &gt; 110 bpm , atrial flutter , prolong QT &gt; 500 msec , second third degree atrioventricular [ AV ] block treat pacemaker ) New York Heart Association Class III IV congestive heart failure Severe hepatic insufficiency ( defined alanine aminotransferase [ ALT ] , aspartate aminotransferase [ AST ] , gammaglutamyl transferase &gt; 3 time upper limit normal [ ULN ] , total bilirubin &gt; 2 mg/dL , ChildPugh B C ) active hepatitis investigator 's opinion A schedule surgery may expect lead significant blood loss</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Anemia CKD dialysis</keyword>
</DOC>